Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatocellular Carcinoma Recurrent: early-phase trial registry
2 of 2 indexed Hepatocellular Carcinoma Recurrent trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Hepatocellular Carcinoma Recurrent: 2 US clinical trials tracked, 2 recruiting.
Hepatocellular Carcinoma Recurrent is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is SCG Cell Therapy Pte., running 1 of these trials.
Enrollment posture brief
Registry condition hepatocellular-carcinoma-recurrent
OPEN 2 | RECR 100% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Hepatocellular Carcinoma Recurrent lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatocellular Carcinoma Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatocellular Carcinoma Recurrent is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
Barbara Ann Karmanos Cancer Institute
NCT07118202
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
SCG Cell Therapy Pte.
NCT05417932
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatocellular Carcinoma Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatocellular Carcinoma Recurrent trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatocellular Carcinoma Recurrent page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Hepatocellular Carcinoma Recurrent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- SCG Cell Therapy Pte. sponsors the most Hepatocellular Carcinoma Recurrent trials on record, review their full trial history before evaluating a specific study. See SCG Cell Therapy Pte.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatocellular Carcinoma Recurrent condition card totals 2 registered trials; most-linked intervention TheraBionic P1; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.